北京美科美生物公司代理AMIDEBIO

Amyloid Peptides
Amyloid Kits and Buffers
Bowman-Birk Inhibitors
Brazzeins
Proinsulin
Toxins and Knottins

AMIDEBIO是一家处于临床前阶段的生物技术公司，致力于糖尿病相关代谢疾病领域的一系列治疗目标和诊断。该公司的主导项目专注于新型葡萄糖反应性胰岛素(GRIs)，通过单次每周剂量，消除对基础胰岛素和膳食胰岛素的需求。该项目利用了该公司的新颖见解，计算设计能力和强大的IP位置在快速制造的超纯生物制剂。重要的是，这些新型GRIs不需要复杂的化学修饰，可以实时对血糖水平做出反应，有望显著改善血糖控制，几乎消除低血糖事件。尽管AMIDEBIO专注于将一种新型GRI引入临床，但我们仍在开发稳定的溶液型胰高血糖素，用于人工胰腺泵和治疗罕见疾病，如先天性高胰岛素血症。此外，我们还将支持我们的传统项目，包括单链胰岛素(SCI)类似物，它在高温下能够抵抗热和化学降解，并通过适当的合作伙伴对T1D进行早期诊断。最后，该公司继续使用我们专有的BioPure™平台技术，为研究团体提供难以生产的多肽，以寻求各种疾病的新治疗方法。
AMIDEBIO is a preclinical stage biotech company pursuing a series of therapeutic targets and diagnostics in the diabetes related metabolic disease space. The companies lead program is focused on novel glucose responsive insulins (GRIs) that will eliminate the need for basal and prandial insulins through a single weekly dose. This program leverages the company’s novel insights, computational design capabilities and strong IP position in rapid manufacturing of ultrapure biologics. Importantly, these novel GRIs do not require complex chemical modifications and respond in real-time to blood glucose levels which is expected to dramatically improve glycemic control and virtually eliminate hypoglycemic events. While AMIDEBIO is focused in bringing a novel GRI to the clinic, we maintain substantial efforts in the development of solution stable glucagon for use in pumps for an artificial pancreas and the treatment of rare diseases such as congenital hyperinsulinism. In addition, we will support our legacy programs including single chain insulin (SCI) analogs that are resistant to thermal and chemical degradation at elevated temperature and early diagnostics for T1D through appropriate partnerships. Finally, the company continues to use our proprietary BioPure™ platform technology to deliver difficult-to-manufacture peptides for the research community in the pursuit of novel treatments for a variety of diseases.